Navigation Links
Cappella Inc. Secures $17.3 Million Series C Investment
Date:6/14/2009

c point in the company's development. From our perspective, Cappella have a differentiated product offering for the treatment of coronary heart disease. Cappella's impressive management team and top-class scientific advisory board will drive rapid adoption of the Sideguard(TM) Sidebranch stent in Europe and its successful clinical development in the US."

Masashi Kiyomine, Principal at Mitsui & Co. Venture Partners, commented: "We are very pleased to have co-led this important round of financing for Cappella, to support the global commercial success of the Sideguard(TM) Sidebranch stent. With an experienced management team led by Dr. Rosenthal, we believe Cappella is ideally positioned to become the leading provider of innovative solutions for the treatment of bifurcation vascular disease - an area of high unmet medical need."

Dr Wolfgang Oster, Managing Partner at Polytechnos Venture Partners and Chairman of Cappella's Board, noted: "As founding investors of Cappella, we are delighted to close this substantial round of finance for a company which we believe has the potential to lead the field of bifurcation devices. The commercial expertise which the new investors bring to the table in Europe, US and Japan is reassuring and will help to accelerate the company's marketing efforts of its device portfolio. Importantly, the continued participation of our syndicate partners, in particular ACT Venture Capital, in our common cause was a prerequisite to get the company to this exciting value inflection point."

In addition to Dr. Wolfgang Oster, Dr. Art Rosenthal and Dr. Ena Prosser, other Board seats will be held by Masashi Kiyomine, MCVP, Dr. Ascher Shmulewitz company co-founder, Cappella's Vice Chairman Charlie Glass of ACT Venture Capital and Dirk Kanngiesser, Polytechnos Venture Partners.

About Cappella Inc

Cappella, Inc. ("Cappella" or the "Company") is a medical device company
'/>"/>

SOURCE Cappella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Hyperion Therapeutics Secures $40 Million In Series B Round
3. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
4. Altheus Therapeutics Secures $3.6 Million in Venture Capital
5. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
6. Dendreon Secures $130 Million Committed Equity Financing Facility
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Taligen Therapeutics Secures Series B Financing
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
11. Amarin Secures Global Intellectual Property Rights for Lipid Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... financial results will be released on,Thursday, July 31, 2008. ... at 10:00 a.m. Eastern Time, July 31, 2008, to ... hosted by Steven G.,Anderson, president and CEO of CryoLife, ...
... a disease that strikes an average of 4000 Belgians ... not yet clear. But now, VIB researchers connected to ... cleavage of the Nrg-1 protein lies at the basis ... this molecular process is a first step toward improved ...
... Makes it Easy to Connect with Technology ... on Specific Chemical Reactions, PRINCETON, N.J., July ... portal for manufacturers that require service,and support in ... bio-technology products, industrial products and,higher-value chemicals. The all-new ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2Incorrectly cleaved protein leads to schizophrenia 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 2Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise 3
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
... statistical pattern recognition and image processing to help ... , Under a grant funded by the ... Science Foundation, UC San Diego structural engineering professor ... imagery-based surveillance technique which uses visible and infrared ...
... medical experts in the burgeoning field of interventional ... gather in Las Vegas July 20-23 for the ... from Rush University Medical Center in Chicago will ... course of symposium. On Monday, July 21st, ...
... success when they can thrive without killing their host. ... California Institute of Technology have uncovered how one such ... from the immune system. The human immune system ... a continual dance for survival--viruses ever seek new ways ...
Cached Biology News:UC San Diego researchers could help US military thwart explosive threats 2UC San Diego researchers could help US military thwart explosive threats 3Latest advances in interventional cardiology for congenital heart disease presented 2A viral cloaking device 2A viral cloaking device 3
... Automated instrument designed to hold up to 6 ... robust and easy to use design ensures that ... regular cyclic stretching or compression. This unit allows ... the strain to produce 64 unique strain settings. ...
... Cell Lab Quantas unique combination of ... population resolution capabilities and accurate cell ... excitation wavelengths, including UV, allowing flexible ... multi-color applications typically only achievable with ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... g monoclonal antibody irreversibly crosslinked to protein ... of PDH complex from heart mitochondria. Also ... mitochondria for control immunocapture. ,The pyruvate dehydrogenase ... PDH from small amounts of tissue. This ...
Biology Products: